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PURPOSE: To study the results including long-term follow-up obtained with endovascular treatment of patients with
intermittent claudication who did not experience clinical improvement with conservative treatment.
METHODS: From January 1992 to January 2002, 62 of 1380 patients (4.5%) with intermittent claudication underwent
endovascular treatment and were followed up for up to 120 months (mean 76 months). The variables analyzed were the
functioning of the arterial segment undergoing the endovascular procedure, the evolution of the maximum walking dis-
tance, and incidence of related morbidity and mortality.
RESULTS: Fifty-two patients (84%) experienced no walking limitation after the procedure, and 6 patients (10%) improved
but still exhibited some degree of limitation, for a total improved outcome of 94%. The patency rate was 82%. There was no
intraoperative mortality. One primary failure and one immediate thrombosis occurred, and both were surgically corrected.
Thrombosis of the treated artery occurred in 6 patients 12, 16, 25, 29, 62, and 66 months after the procedure. These patients
started to experience intermittent claudication with a walking distance to onset that was similar to their presurgical distance
to onset. During follow-up, a mortality rate of 12.9% (8 patients) was observed, 6 due to myocardial infarctions and 2 due
cerebral infarction. Three patients underwent coronary bypasses 22, 36, and 55 months after the endovascular surgery, and
2 patients underwent coronary angioplasty after 6 and 26 months. The mean follow up period was 76 months (range 0-120
months).
CONCLUSION: This study shows that endovascular treatment of intermittent claudication brought about a lasting regres-
sion of the ischemic conditions in a significant number of patients, with excellent patency rates. It was concluded that this
is a good alternative for selected patients, with low rates of complications and positive long-term results.
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For patients with critical ischemia, revascularization is
the procedure of choice for limb salvage. Endovascular pro-
cedures and arterial grafting are the prescribed methods.1,2
For patients with intermittent claudication (IC), the goal of
the treatment is the improvement of quality of life through
increasing the walking distances.
The relatively benign natural evolution of IC3,4 and the
dubious surgical results obtained in the 1960s and 1970s5
have justified conservative treatment for the majority of
cases. Thus, in our service, a clinical approach has been used
in the initial stage of treatment. After a period of physical
training, the therapeutic response is evaluated. When a good
response is not achieved and the patient is in good physi-
cal condition, revascularization is proposed, which allows
for immediate benefits to be obtained.6,7
The use of endovascular surgery in cases of IC has been
increasing progressively. However, there are few prospec-
tive studies that analyze its results among individuals who
had not obtained improvement through clinical treatment,
especially with long-term follow-up.
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The goal of this work was to prospectively study results
obtained through endovascular treatment of patients with
IC who did not gain sufficient clinical improvement via
conservative treatment, including a long-term (76 months
with a range of 0-120 months) follow-up.
PATIENTS AND METHODS
During the period from January 1992 to January 2002,
62 patients who underwent endovascular treatment for IC
were followed up. These were a subset of a group of 1380
patients with this condition who were admitted during this
period to an outpatient service for peripheral obstructive
arterial disease and IC. The patients undergoing
endovascular procedures represented 4.5% of the total.
All the patients treated in our service followed the se-
quence of therapeutic options presented in Figure 1.
The clinical approach (unsupervised physical training
and treatment of the risk factors for peripheral obstructive
arterial disease) was used in the initial phase of treatment.
After a period of clinical treatment lasting for at least 6
months, the therapeutic response was analyzed. When the
walking distance improved, the clinical treatment was main-
tained. If claudication worsened, or if no change was ob-
served, patients were offered the options of maintaining
clinical treatment or undergoing endovascular treatment
(Figure 1).
As a result of this therapeutic strategy, only 380 (27.5%)
out of the 1380 patients treated for IC in our institution, ex-
perienced no increase in their walking distance capability
after a minimum period of 6 months of unsupervised clini-
cal treatment. Of these 380 patients with poor results, 55 (4%)
evolved to ischemia that threatened to produce limb loss,
and for these, revascularization was formally indicated as a
form limb saving therapy. For the remaining 325 (23.5%),
revascularization was suggested for improving the walking
distances. The majority of these patients (237 or 17.2%) pre-
ferred to continue with the clinical treatment because they
did not want to run the risks inherent in the endovascular
procedures, while the other 88 (6.2%) decided to avail them-
selves of this alternative. Thus, 26 surgical procedures (1.8%)
and 62 endovascular procedures (4.5%) were performed. It is
the latter group that is presented in this study.
The 62 patients (48 male, 14 female) who underwent
endovascular procedures, had an average age was 58.7 years
(46 to 69 years); of these, 54 (87.1%) were smokers, 24
(40%) were hypertensive, and 15 (24%) were diabetic.
The average duration of the claudication, from its ap-
pearance until the time of the surgery was 22 months, with
a range of 8 to 46 months.
No patient included in this study presented ischemic
pain at rest, tissue loss, or gangrene of ischemic cause. The
average ankle-arm index was 0.62. No patient presented ar-
terial pressure in tibial arteries lower than 40 mm Hg.
All the patients underwent preoperative digital arteri-
ography or angioresonance to determine the type of arte-
rial revascularization to be employed in each case.
Endovascular procedures were performed on the patients
who presented obstructive disease in aortoiliac arterial seg-
ments of lengths shorter than 5 cm and in femoropopliteal
arterial segments of lengths shorter than 3 cm. Patients who
presented lesions of lengths greater than 5 cm were treated
by surgical bypasses and are not included in this study.
Aortoiliac disease was observed in 52 patients and
femoropopliteal disease in 10.
To objectively assess the severity of IC, we measured
the maximum walking distance (MWD) using a progressive
treadmill test. This was done at a constant velocity of 3.2
km/hr, initially on level (0 degrees), then with a progres-
sive increase of 2% in the inclination every 2 minutes. The
test was performed until pain prevented the patient from
continuing to walk, and this value was also kept as com-
parison standard for the follow-up period.8 The average
MWD before surgical treatment was 160 m (range: 50 to
200 m) for this sample of patients.
The vascular evolution was determined through periodic
measurements of the walking distance values obtained in
equivalent treadmill tests performed at every return visit.
The evolution was considered to be favorable when there
was an increase of more than 50 meters in the distance
walked. The remaining cases were considered to present
unfavorable evolution.
_______ Natural (accepted) sequence of treatment.
———— Alternative sequences that may or may not be used.
Figure 1 - Treatment scheme for Intermittent Claudication.
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The endovascular procedures employed are shown in
Table 1.
All procedures were performed in the operating room
under epidural anesthesia. For the uni-iliac procedure, ac-
cess was gained by ipsi-lateral retrograde puncture, except
in 1 patient who underwent open access arterial surgery. For
the aortic and bi-iliac procedures, bilateral retrograde punc-
ture was used. For the femoro-popliteal procedures, antero-
grade puncture of the common femoral artery was used, ex-
cept in 1 patient for whom it was suspected that arterial dis-
section on the same side would be required. In this case,
inguinotomy and direct exposure of the common femoral
artery was the chosen approach.
After placement of the guidewire, a 7F catheter was in-
serted so intravenous anticoagulant heparin therapy could
be administered. After crossing the lesion with the
guidewire, we dilated the lesion with a balloon and then
placed the stent. In all cases we used the Palmaz stent. An-
giographies were performed immediately before and after
balloon dilation and after placement of the stent.
All patients, except 2 who had complications, were dis-
charged 1 day after the procedure. The 2 patients with com-
plications were discharged after 10 and 27 days.
All patients were treated with antiplatelet agents after
the procedure (AAS 100 mg/day or ticlopidine 500 mg/
day), and de-ambulation was recommended.
Patients were reevaluated after 3 months and 6 months,
and at 6 months intervals thereafter. The follow-up dura-
tion ranged from 9 to 114 months, with an average of 76
months. At each visit, the treadmill test was performed and
the MWD was determined. The patency of the treated arte-
rial segments that underwent angioplasty and stent deploy-
ment was confirmed by means of physical examination and
color duplex sonography.
The variables analyzed were the functioning of the ar-
terial segment that underwent the endovascular procedure,
the evolution of the MWD, patency, morbidity, and mor-
tality.
RESULTS
There was 1 primary failure, in a patient who underwent
iliac stent insertion. The patient immediately underwent an
iliac-femoral bypass with good clinical results.
There was 1 immediate thrombosis in a patient who un-
derwent a uni-iliac stent procedure. This patient immedi-
ately underwent femorofemoral bypass, but she developed
ischemic gangrene and finally underwent amputation be-
low the knee.
There were no other cases of worsening of the degree of
ischemia, nor were there any intraoperative deaths in this
group.
Fifty-two patients had no remaining walking limitation
after the procedure (i.e. they were able to complete a dis-
tance of 1000 m in the treadmill test). Six patients experi-
enced significant improvement, although with some degree
of limitation (i.e. they achieved 420 ± 150 m in the tread-
mill test), and 4 presented a small improvement in their
maximum walking distance (less than 50 meters). Thus, 58
patients presented favorable evolution, and only 4 had
unfavorable evolution.
During the follow-up, 6 patients presented thrombosis
of the treated artery, which occurred 12, 16, 25, 29, 62, and
66 months after the procedure. After their occlusions, these
patients started to suffer from IC with onset at presurgical
distances. These patients were walking distances that did
not inhibit their basic activities. We observed relapse to pre-
vious claudication levels in 3 other patients due to disease
progression in the femoropopliteal segment. These occurred
in patients who had previously undergone iliac stent inser-
tion.
The overall mortality rate including the follow-up pe-
riod was 12.9%. Six patients suffered acute myocardial
infarctions 21, 26, 29, 36, 48, and 68 months after the
endovascular procedure, and died. Two patients died be-
cause of cerebral infarction 32 and 52 months after the
endovascular procedure.
Regarding morbidity, 3 patients underwent coronary
bypass surgery 22, 36, and 55 months after the
endovascular surgery, and 2 patients underwent coronary
angioplasty 6 and 26 months after surgery. One patient had
a cerebral infarct 39 months after the procedure with total
clinical regression, and 1 patient has been undergoing di-
alysis which started 38 months after the procedure.
The results of the long-term patency are shown in Ta-
ble 2 and Figure 2.
DISCUSSION
At the beginning of the revascularization era in the
1960s and 1970s, it was thought that the natural evolution
of IC would be an inexorable progression of ischemia until
consequent loss of the limb, which appeared to justify early
Table 1 – Procedures performed.
Procedures Number of Patients
Uni-iliac stent 44
Aortic stent 3
Bi-Iliac stent 5
Femoro-popliteal stent 10
Total 62
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surgical treatment. However, the surgical techniques and
equipment available at that time were less developed than
those of today, and results were debatable.5 Although the
risk of limb loss with conservative treatment does exist, stud-
ies using large samples have demonstrated that this progres-
sion is unusual. Boyd et al. studied 1440 patients with IC
and reported that, after 10 years, 12.2 % had required am-
putation.9 In the Framingham study, only 1.6 % of claudi-
cation patients required amputation within a period of 8.3
years.10
Since patients treated clinically were being seen to
present low amputation rates, the clinical approach came
to be used with more confidence, safety, and frequency from
the 1970s onwards,3 thus relegating surgical treatment to a
secondary position.
Reduction in the risk of limb loss has ceased to be the
main objective of treatment. In fact, the objective has shifted
to improvement of the quality of life of IC sufferers by re-
ducing their physical limitations while always respecting
the risks and benefits of each procedure.11
On the basis of this notion, our service began to use the
sequence of therapeutic options presented in Figure 1.
Since 1964, when Dotter et al.12 performed the first
angioplasties in the femoropopliteal region using rigid
Table 2 - Long-term cumulative primary patency of endovascular procedures
No of patients Patency
Interval (months) At risk Failed Deaths Withdrawn Lost/Total Interval Cumulative Standard Error
0 – 1 62 2 0 0 0 96.8 96.8 0.0221
1 – 3 60 0 0 1 0 100.0 96.8 0.0225
4 – 6 59 0 0 2 0 100.0 96.8 0.0228
07 – 12 57 1 0 2 0 98.2 95.0 0.0283
13 – 18 54 1 0 1 0 98.1 93.3 0.0331
19 – 24 52 0 1 1 0 100.0 93.3 0.0339
25 – 30 50 2 2 0 0 95.9 89.5 0.0415
31 – 36 46 0 2 3 0 100.0 89.5 0.0440
37 – 42 41 0 0 5 0 100.0 89.5 0.0468
43 – 48 36 0 2 0 1 100.0 89.5 0.0494
49 – 54 33 0 0 2 1 100.0 89.5 0.0517
55 – 60 30 0 0 4 1 100.0 89.5 0.0554
61 – 66 25 1 0 1 0 95.9 85.8 0.0653
67 – 72 23 1 1 0 0 95.6 82.0 0.0733
73 – 78 21 0 0 0 0 100.0 82.0 0.0809
79 – 84 16 0 0 5 0 100.0 82.0 0.0914
85 – 90 13 0 0 3 0 100.0 82.0 0.0984
91 – 96 12 0 0 1 0 100.0 82.0 0.1129
097 – 102 7 0 0 4 1 100.0 82.0 0.1483
103 – 108 4 0 0 3 0 100.0 82.0 0.1740
109 – 114 4 0 0 0 0 100.0 82.0 0.2200
115 – 120 1 0 0 3 0 100.0 82.0 0.3479
121 – 126 1 0 0 0 0 100.0 82.0 0.3479
Figure 2 - Cumulative primary patency rates of 62 consecutive angioplasties performed for intermittent claudication.
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metal catheters, a new set of endovascular procedures that
provide an alternative to conventional arterial surgery for
the treatment of arterial obstructions has been developed.13
The first type of endovascular treatment used was
angioplasty. Despite being conceptualized in the 1960s,
angioplasty only became an applicable technique from the
1970s onwards, with the introduction of the balloon cath-
eters devised by Gruntzig.14. In this procedure, a balloon is
inserted into the artery and positioned precisely over the
atherosclerotic plaque. By insufflation of the balloon, the
stenotic plaque is ruptured and partially separated from the
vascular wall, thereby resulting in a significant increase in
the arterial lumen.
Technological advances achieved over recent decades,
comprise improvements in the acquisition of vascular
imaging and the development of new catheters, drugs, and
complementary accessories for angioplasty. Such accesso-
ries include thrombolytic agents, stents, and endoprostheses
that can be used for improving the results of angioplasty.15,16.
At present, angioplasty and stent angioplasty are the
endovascular procedures most frequently used in patients
with localized obstructive arterial lesions in the aortoiliac
segment. We have opted for the second option from the start
of this study, because we believe in the advantages of
stenting angioplasty, as evidenced in the TransAtlantic In-
ter-Society Consensus 17. Meanwhile, angioplasty is also a
good option.
In our sample, we observed that 83.8% of the patients
presented aortoiliac disease, and only 16.2% presented dis-
ease in the infra-inguinal segment. This is due to the fact
that endovascular revascularization in more proximal
(aortofemoral) segments favors a good evolution,18 which
is why endovascular revascularization of the more proxi-
mal aortofemoral segments is indicated more frequently. In
femoropopliteal obstructive arterial disease, it has been
demonstrated that angioplasties associated with stent place-
ment above the knee in very short lesions (less than 3 cm)
have good results.2
Endovascular techniques and materials have undergone
great improvements over the years. This has allowed im-
provements in the immediate and long-term results, as is
evident in the literature in general,2,19 as well as in our sam-
ple, in which we had primary failure in only 2 cases (3.2%)
and a patency rate of 82% after an average of 76 months of
follow-up.
With respect to evolution, attention must be paid to late
obstructive complications. Non-obstructive complications
are not frequent and have not yet been seen in our sample.
The fact that only 1 patient from our sample had critical
ischemia suggests that these were patients with less severe
arterial disease and better prognosis, rather than the more
compromised type of patient that has severe clinical mani-
festations. On the other hand, since all the operations in
this study were performed on an elective basis, all our pa-
tients were submitted to surgery their best possible clinical
conditions.
Atherosclerotic disease progression is a significant rea-
son for the recurrence of ischemic symptoms in the lower
limbs.20 In our series, even with the control of risk factors
and a close follow-up, 6 patients (9.6%) presented throm-
bosis in the treated artery, and 3 other patients (4.8%) pre-
sented distal occlusions, probably because of the longer fol-
low-up period, which had allowed evolution of the athero-
sclerotic disease.
Despite the fact that such patients are considered to
present moderate surgical risk, we did not observe
intraoperative mortality among this sample, probably be-
cause endovascular procedures are less invasive than con-
ventional surgery. On the other hand and in conformity
with other samples,21 we observed a mortality rate of 12.9%
over our average follow-up time of 76 months. The main
cause of death was acute myocardial infarct (9.6%). In ad-
dition to this, 5 patients (8.0%) underwent cardiac
revascularization during this period. These data confirm
data found other reports and also confirm the consensus that
occlusive disease of the lower limbs is an important marker
for associated coronary disease.22
The treatment of IC has been evolving and is being re-
fined with knowledge of its natural history through the use
of different physical training techniques, surgical tech-
niques, and endovascular techniques that are steadily be-
coming more developed.
The clinical approach (physical training) has in its favor
its noninvasive nature, with a low incidence of complica-
tions,23-26 as well as its systemic action. It tends to improve
walking distance capability in a slow and gradual manner,
bringing benefits to the whole cardiovascular system and
interrupting or at least diminishing the progression of the
atherosclerotic disease.4,27-31 Nonetheless, to obtain the de-
sired effect, great effort is required from the patient, and
treatment takes a long time.
The endovascular approach is defensible because of its
immediate benefits.32,33 In our sample, 93.5% of the patients
presented immediate improvement in their symptomatology
after the surgical procedure. From a socioeconomic point
of view, the rapid reintegration of patients into their habitual
activities, including work, and especially among younger
patients, justifies the adoption of this type of therapy more
frequently.34 Another advantage of endovascular treatment
is the benefit enjoyed by patients during the period while
they are free from late complications. These patients enjoy
a good quality of life beginning in their postoperative pe-
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riod and extending until late-stage cardiovascular events
occur, which took place in 24.2% of our sample of patients.
Available published data combined to our personal ex-
perience over the last 10 years has allowed us to give pa-
tients with IC up-to-date information regarding their prog-
nosis, with a comfortable safety margin. On the other hand,
the results from the present study and those from other stud-
ies regarding endovascular treatment of IC lead to the con-
clusion that this is a very mature option, as a result of the
sophistication and refinement of techniques and technolo-
gies.24,25,35 Although the indication for endovascular surgery
for IC is still the exception, the results contrast greatly with
those of earlier years that led to the relegation of surgical
treatment to a secondary position.
In making a detailed analysis of our sample, it can be
noted that only the patients with an unsatisfactory response
to clinical treatment underwent endovascular treatment.
Thus, these patients possibly had a worse prognosis than
those that responded well to clinical treatment. It is possi-
ble that the patients who underwent surgical treatment pre-
sented arterial margins that were more compromised, dis-
ease of a more aggressive character, or muscle conditions
that were less favorable than those present in the patients
who improved with clinical treatment. Thus, considering
the good results obtained with this sample, we may infer
that the surgical treatment of patients who do not necessar-
ily present improvement with clinical treatment will possi-
bly bring results that are equal to or even more promising
than clinical treatment. We believe that the role of
endovascular surgery in the treatment of IC must be recon-
sidered in the sense of expanding its coverage.
In our study, the results from endovascular treatment of
IC brought about a lasting regression of the ischemic con-
ditions in a significant number of patients, with excellent
patency rates. We conclude that this is a good alternative
for selected patients, with low rates of complications and
positive long-term results.
RESUMO
Wolosker N, Nakano L, Rosoky RA, Munia MA, Muraco
Netto B, Puech-Leão P. Tratamento endovascular para
pacientes portadores de Claudicação Intermitente que
não melhoram com tratamento clínico. Clinics.
2005;60(3):193-200.
OBJETIVO: Estudar a longo prazo (média de 76 meses de
seguimento) os resultados obtidos com o tratamento
endovascular em pacientes que não melhoram com o trata-
mento clínico,
MÉTODOS: De Janeiro de 1992 a Janeiro de 2002, 62 pa-
cientes de um grupo de 1380 claudicantes foram submeti-
dos a tratamento endovascular, representando 4,5% do to-
tal. As variáveis analisadas foram o funcionamento do seg-
mento arterial submetido ao procedimento endovascular, a
evolução da distância máxima de marcha e a ocorrência de
morbi-mortalidade.
RESULTADOS: Cinqüenta e dois (84%) pacientes não apre-
sentaram restrições à deambulação após o procedimento.
Seis pacientes melhoraram, representando um benefício de
94%. Não houve mortalidade intra-operatória. Uma falên-
cia primária e uma trombose imediata foram corrigidas ci-
rurgicamente. Seis pacientes apresentaram trombose da ar-
téria tratada 12, 16, 25, 29, 62 e 66 meses após o procedi-
mento e voltaram a apresentar Claudicação Intermitente
para as mesmas distâncias referidas antes da cirurgia. Du-
rante o seguimento foi observada taxa de mortalidade de
12,9% (8 pacientes), dos quais 6 por infarto do miocárdio
e dois por acidente vascular cerebral. Três pacientes foram
submetidos à revascularização miocárdica 22, 36 e 55 me-
ses após o procedimento endovascular e duas angioplastias
foram realizadas com 6 e 26 meses de seguimento. O tem-
po médio de segmento foi de 76 meses (0 a 120 meses).
CONCLUSÃO: O tratamento endovascular da Claudicação
Intermitente levou a melhora das condições da marcha em
um número significativo de pacientes, com excelentes ta-
xas de patência (82,0%). Concluímos que esta é uma boa
alternativa para determinados pacientes, com poucas com-
plicações e resultados positivos a longo prazo.
UNITERMOS: Tratamento endovascular. Claudicação
Intermitente. Tratamento clínico. Stent. Angioplastia.
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